

Alzheimer's Disease (AD)

## An Open-Label Crenezumab Study in Patients With Alzheimer's Disease

**Trial Status**  
Terminated

**Trial Runs In**  
16 Countries

**Trial Identifier**  
NCT03491150 2017-002702-12  
BN40031

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03491150 2017-002702-12 BN40031**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
All

**Healthy Volunteers**  
No

---